Login to Your Account

Phase II Brain-Injury Win with Vasopharm's NO Inhibitor

By Nuala Moran
Staff Writer

Monday, September 17, 2012
LONDON – Vasopharm GmbH announced that the Phase IIa trial of its nitric oxide inhibitor VAS203 not only cleared all the safety, tolerability and pharmacokinetic hurdles, but also led to "substantially improved" neurological recovery at six months in traumatic brain injury (TBI) patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription